Denali Therapeutics Inc (DNLI) Quality Analysis

DNLI GoodMoat Verdict

Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.

Run Stock X-Ray →

DNLI Profitability

Profitability trend analysis coming soon

DNLI Growth

Growth trend analysis coming soon

DNLI Financial Health

Financial health indicators coming soon

DNLI Quality & Fundamental Analysis

Denali Therapeutics Inc (DNLI) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Denali Therapeutics Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.

Denali Therapeutics Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. and a return on equity (ROE) of -50.11%. Return on assets (ROA) stands at -44.37%.

The debt-to-equity ratio is 0.03, with a current ratio of 9.16.

GoodMoat's quality analysis uses AI-powered insights to evaluate whether Denali Therapeutics Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.